SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.

导出 LinkOut

翻译打印收藏纠错

作者： Yasunori,Sato ; Hideki,Ueno ; Tatsuya,Ioka ; Shinichi,Ohkawa ; Masafumi,Ikeda ; Tomotaka,Shimamura ; Akihito,Tsuji ; Yoshiaki,Tsuchiya ; Junji,Furuse ; Hiroshi,Ishii ; Ken,Furuya ; Haruo,Iguchi ; Yoshihiro,Saito ; Nahoko,Kaniwa ; Jun-Ichi,Sawada ; Hiromi,Sakamoto ; Akihiro,Sekine ; Takuji,Okusaka ; Teruhiko,Yoshida ; GEST

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);脱氧胞苷(Deoxycytidine);复方合剂(Drug Combinations);女(雌)性(Female);基因型(Genotype);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);中年人(Middle Aged);氧嗪酸(Oxonic Acid);胰腺肿瘤(Pancreatic Neoplasms);多态性, 单核苷酸(Polymorphism, Single Nucleotide);预后(Prognosis);喃氟啶(Tegafur)

DOI 10.1097/MPA.0000000000001052

PMID 29683977

发布时间 2022-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Pancreas

637-642页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.

Pancreas

相似文献

Pancreas

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.

Pancreas

相似文献

Pancreas

相关期刊

检索历史清除